Effects of somatostatin analogues on acromegalic cardiomyopathy: Results from a prospective study using cardiac magnetic resonance

[1]  F. Bogazzi,et al.  Identification, treatment and management of cardiovascular risks in patients with acromegaly , 2008, Expert review of endocrinology & metabolism.

[2]  G. Aquaro,et al.  High prevalence of cardiac hypertophy without detectable signs of fibrosis in patients with untreated active acromegaly: an in vivo study using magnetic resonance imaging , 2008, Clinical endocrinology.

[3]  M. Cosottini,et al.  Prevalence and functional significance of antipituitary antibodies in patients with autoimmune and non-autoimmune thyroid diseases. , 2007, The Journal of clinical endocrinology and metabolism.

[4]  R. Nijveldt,et al.  Delayed contrast enhancement magnetic resonance imaging for the assessment of cardiac disease. , 2007, Heart, lung & circulation.

[5]  M. Galderisi,et al.  Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. , 2007, The Journal of clinical endocrinology and metabolism.

[6]  D. Bluemke,et al.  MRI to Assess Arrhythmia and Cardiomyopathies: Relationship to Echocardiography , 2007, Echocardiography.

[7]  G. Maira,et al.  The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly , 2007, Pituitary.

[8]  S. Nagueh,et al.  Noninvasive cardiac imaging in patients with hypertrophic cardiomyopathy. , 2006, Journal of the American College of Cardiology.

[9]  P. Cappabianca,et al.  First-line therapy of acromegaly: A statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group , 2006, Journal of endocrinological investigation.

[10]  Dudley J Pennell,et al.  Reference right ventricular systolic and diastolic function normalized to age, gender and body surface area from steady-state free precession cardiovascular magnetic resonance. , 2006, European heart journal.

[11]  G. Tonti,et al.  Myocardial systolic strain abnormalities in patients with acromegaly: A prospective color Doppler imaging study , 2006, Journal of endocrinological investigation.

[12]  Michael Jerosch-Herold,et al.  Utility of Cardiac Magnetic Resonance Imaging in the Diagnosis of Hypertrophic Cardiomyopathy , 2005, Circulation.

[13]  M. Mariani,et al.  Improvement of intrinsic myocardial contractility and cardiac fibrosis degree in acromegalic patients treated with somatostatin analogues: a prospective study , 2005, Clinical endocrinology.

[14]  C. Bartolozzi,et al.  MRI of the Heart and Vessels , 2005 .

[15]  Warren J Manning,et al.  Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. , 2004, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[16]  D. Pennell,et al.  Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography , 2004, Heart.

[17]  P. Marzullo,et al.  Systemic complications of acromegaly: epidemiology, pathogenesis, and management. , 2004, Endocrine reviews.

[18]  G. Vitale,et al.  Cardiovascular Complications in Acromegaly: Methods of Assessment , 2001, Pituitary.

[19]  P. Chanson,et al.  Diagnosis and treatment of acromegaly complications , 2003, Journal of endocrinological investigation.

[20]  R. Clayton.  Cardiovascular function in acromegaly. , 2003, Endocrine reviews.

[21]  S. Plein,et al.  Normal human left and right ventricular dimensions for MRI as assessed by turbo gradient echo and steady‐state free precession imaging sequences , 2003, Journal of magnetic resonance imaging : JMRI.

[22]  D. Bonaduce,et al.  Reversal of acromegalic cardiomyopathy in young but not in middle‐aged patients after 12 months of treatment with the depot long‐acting somatostatin analogue octreotide , 2003, Clinical endocrinology.

[23]  C. Mady,et al.  Treatment of acromegaly improves myocardial abnormalities. , 2002, American heart journal.

[24]  P. Marzullo,et al.  Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. , 2002, European journal of endocrinology.

[25]  P. Marzullo,et al.  Growth hormone and the heart , 2001, Clinical endocrinology.

[26]  I. Lancranjan,et al.  Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. , 2000, The Journal of clinical endocrinology and metabolism.

[27]  F. Magrini,et al.  Blood pressure-independent cardiac hypertrophy in acromegalic patients. , 1999, Journal of hypertension.

[28]  A. Devlin,et al.  A comparison of MRI and echocardiography in hypertrophic cardiomyopathy. , 1999, The British journal of radiology.

[29]  A. Gulino,et al.  Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients. , 1999, The Journal of clinical endocrinology and metabolism.

[30]  M. Salvatore,et al.  Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly. , 1999, The Journal of clinical endocrinology and metabolism.

[31]  P. Marzullo,et al.  Cardiovascular aspects in acromegaly: effects of treatment. , 1996, Metabolism: clinical and experimental.

[32]  P. Marzullo,et al.  Growth hormone and the heart , 2001, Endocrine Updates.

[33]  B. Biondi,et al.  Impaired cardiac performance is a distinct feature of uncomplicated acromegaly. , 1994, The Journal of clinical endocrinology and metabolism.

[34]  B. Biondi,et al.  Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly. , 1993, The Journal of clinical endocrinology and metabolism.

[35]  M. Komajda,et al.  Cardiac hypertrophy and function in asymptomatic acromegaly. , 1991, European heart journal.